{"filing":{"accession_number":"0001837607-26-000055","cik":"0001837607","ticker":"AEON","company_name":"AEON Biopharma, Inc.","form":"8-K","filing_date":"2026-07-23","report_date":null,"primary_document":"aeon-20260723x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000055/aeon-20260723x8k.htm"},"events":[{"id":19993,"run_id":18000,"accession_number":"0001837607-26-000055","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"AEON Biopharma completed a public offering on July 15, 2026, and on July 23, 2026 issued an additional 4,696,102 shares of Class A common stock pursuant to a partial exercise of the underwriters' over-allotment option, generating approximately $1.5 million in gross proceeds ($1.4 million net). This is a dilutive equity issuance that increases shares outstanding and raises capital, fitting the dilutive_issuance category. The disclosure also references previously exercised over-allotment options for milestone warrants, further evidencing equity dilution.","company_name":"AEON Biopharma, Inc.","ticker":"AEON","filing_date":"2026-07-23","form":"8-K","submitted_at":null,"items":[{"id":19239,"accession_number":"0001837607-26-000055","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"AEON Biopharma completed a public offering on July 15, 2026, and on July 23, 2026 issued an additional 4,696,102 shares of Class A common stock pursuant to a partial exercise of the underwriters' over-allotment option, generating approximately $1.5 million in gross proceeds ($1.4 million net). This is a dilutive equity issuance that increases shares outstanding and raises capital, fitting the dilutive_issuance category. The disclosure also references previously exercised over-allotment options for milestone warrants, further evidencing equity dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:03:48.858864+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19239,"accession_number":"0001837607-26-000055","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"AEON Biopharma completed a public offering on July 15, 2026, and on July 23, 2026 issued an additional 4,696,102 shares of Class A common stock pursuant to a partial exercise of the underwriters' over-allotment option, generating approximately $1.5 million in gross proceeds ($1.4 million net). This is a dilutive equity issuance that increases shares outstanding and raises capital, fitting the dilutive_issuance category. The disclosure also references previously exercised over-allotment options for milestone warrants, further evidencing equity dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-23T20:03:48.858864+00:00","company_name":"AEON Biopharma, Inc.","ticker":"AEON","filing_date":"2026-07-23"}]}